ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Aptabio to initiate Phase II oral Covid-19 therapy trial pharmaceutical-technology
March 29, 2021South Korean company Aptabio is all set to initiate a Phase II trial of its oral therapy, APX-115, for treating Covid-19.A transmembrane enzyme NADPH oxidase (NOX) inhibitor, APX-115 was studied in Europe for treating patients with diabetes complications.
Pharma Sources Insight July 2025
